Source: International Congress 2019 – Connective tissue disease-associated interstitial lung disease and hypersensitivity pneumonitis: what’s new?
Disease area: Interstitial lung diseases



Rating:

Share or cite this content

Citations should be made in the following way:
M. Watanabe (Kochi, Japan), Y. Horimasu (Hiroshima, Japan), H. Iwamoto (Hiroshima, Japan), K. Yamaguchi (Hiroshima, Japan), S. Sakamoto (Hiroshima, Japan), T. Masuda (Hiroshima, Japan), T. Nakashima (Hiroshima, Japan), S. Miyamoto (Hiroshima, Japan), S. Ohshimo (Hiroshima, Japan), K. Fujitaka (Hiroshima, Japan), H. Hamada (Hiroshima, Japan), N. Kohno (Hiroshima, Japan), N. Hattori (Hiroshima, Japan). Clinical utility of CCL15 as a prognostic biomarker for hypersensitivity pneumonitis. 3600

Member's Comments

No comment yet.

Related content which might interest you: Prognostic characteristics in chronic hypersensitivity pneumonitis. Source: Virtual Congress 2020 – Diagnostic and prognostic markers for disease-associated interstitial lung disease and hypersensitivity pneumonitis Year: 2020 Clinical significance of serum MRGPRX2 as a new biomarker in allergic asthma Source: International Congress 2019 – Research and innovation in airway diseases Year: 2019 Prognostic factors in chronic hypersensitivity pneumonitis Source: Eur Respir Rev, 29 (156) 190167; 10.1183/16000617.0167-2019 Year: 2020 Diagnostic and prognostic utility of eosinophilic pleural effusions(PE) Source: Eur Respir J 2002; 20: Suppl. 38, 440s Year: 2002 Serum YKL-40 as predictor of outcome in hypersensitivity pneumonitis Source: Eur Respir J , 49 (2) 1501924; DOI: 10.1183/13993003.01924-2015 Year: 2017 Development and validation of a radiological diagnosis model for hypersensitivity pneumonitis Source: Eur Respir J, 52 (2) 1800443; 10.1183/13993003.00443-2018 Year: 2018 Prognostic factors in Korean patients with chronic hypersensitivity pneumonitis Source: International Congress 2018 – CTD-ILD and hypersensitivity pneumonitis: from the bench to the bedside Year: 2018 Is YKL-40 a prognostic marker in sarcoidosis? Source: Annual Congress 2010 - Biomarkers in diffuse parenchymal lung disease Year: 2010 Clinical features of dermatitis, myositis and severe ILD. Could the  AntiSSA / Ro52 antibodies be a diagnostic and prognostic tool for Antisyntatase syndrom? Source: International Congress 2018 – Clinical aspects of hypersensitivity pneumonitis (HP) and CTD-ILD: diagnosis, monitoring and treatment Year: 2018 Clinical prognostic tools and their use in COPD. Source: Virtual Congress 2020 – Clinical and functional evaluation of COPD Year: 2020 Predictive value of clinical diagnosis in sarcoidosis Source: Eur Respir J 2001; 18: Suppl. 33, 345s Year: 2001 Induced sputum TNF-α level as possible prognostic factor in sarcoidosis Source: Eur Respir J 2007; 30: Suppl. 51, 115s Year: 2007 The prognostic value of some clinical and laboratory parameters in sarcoidosis Source: Eur Respir J 2002; 20: Suppl. 38, 434s Year: 2002 Validation of a novel prognostic tool for idiopathic pulmonary fibrosis Source: Annual Congress 2012 - Diffuse parenchymal lung disease I Year: 2012 Sarcoidosis: Clinical course and prognostic predictors Source: Annual Congress 2010 - Management of sarcoidosis and lung manifestations of systemic diseases Year: 2010 The evaluation of serum biomarkers in patients with sarcoidosis: Can visfatin be a new biomarker for sarcoidosis? Source: International Congress 2017 – Rare diseases Year: 2017 Relevant prognostic predictors of sarcoidosis course Source: Eur Respir J 2001; 18: Suppl. 33, 345s Year: 2001 Determining the best diagnostic biomarker for sepsis and prognosis assessment Source: Annual Congress 2012 - Infections and sepsis in the ICU Year: 2012 Clinical diagnosis, monitoring and biomarkers in ILDs Source: ERS Course 2016 Year: 2016 Clinical diagnosis, monitoring and biomarkers in ILDs Source: ERS Course 2019 - Interstitial Lung Diseases Year: 2019